Conditional Replication Viral Vector for Tumor Suppression

The patent changes the proliferation parameter of the viral vector by introducing a conditional replication mechanism. The vector contains an E1A gene that enables replication only in cells expressing specific transcription factors (such as SV40 large T antigen or adenovirus E1A protein), transforming it from a nonproliferating to a conditionally proliferating system. This resolves the contradiction by maintaining safety in normal cells while achieving high incorporation efficiency in target tumor cells through controlled replication.

The patent applies local quality by creating spatially differentiated behavior of the viral vector. The vector is designed to proliferate and exert antitumor activity only in specific locations (tumor cells expressing particular transcription factors) while remaining inert in other locations (normal cells). This is achieved through the conditional replication mechanism that responds to cell-type-specific transcription factors, thereby maintaining high specificity while achieving strong antitumor activity.

The patent applies preliminary action by first introducing the viral vector into the target cells, which then replicate and amplify the gene expression internally. The initial gene introduction requires minimal efficiency, but the subsequent viral replication within the cells serves as a self-amplifying mechanism that enhances gene expression levels. This two-stage process (initial introduction followed by internal amplification through replication) resolves the contradiction between treatment effect and introduction efficiency.